We have put together some introductory resources so you can feel more informed about this new area of practice.
CAR-T Cell Therapy is a new and exciting development in the treatment of haematological cancers.
Introductory resources:
Explaining the Hype: CAR-T Cells
About Car-T Cells (US resource)
Bloodwise UK provides explanation in plain language aimed at a UK audience
UK Patient information (Cancer Research UK)
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
Journal Articles
Journals in Orange are Free/Open Access at the time of posting. The rest are accessible for Christie Staff with Open Athens, and if you are not based at The Christie, will be available via your own Trust Library
*Neurological toxicities associated with chimeric antigen receptor T-cell therapy (Rubin, 2019) Source: Brain, Volume 142, Issue 5, May 2019, Pages 1334–1348
Managing the toxicities of CAR T-cell therapy (Neelapu, 2019) Source: Hematological Oncology; Jun 2019; vol. 37 ; p. 48-52
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.(Grigor et al, 2019) Source: Transfusion Medicine Reviews; Apr 2019; vol. 33 (no. 2); p. 98-110
Associated Toxicities: Assessment and management related to CAR T-cell therapy. (Anderson & Latchford, 2019) Source: Clinical Journal of Oncology Nursing; Apr 2019; vol. 23 ; p. 13-19
*Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis. (Wen-Liang & Zi-Chun, 2019) Source: Cancers; Jan 2019; vol. 11 (no. 1); p. 47-47
CAR T-cell therapy: perceived need versus actual evidence. (The Lancet Oncology, 2018) Lancet Oncology; Oct 2018; vol. 19 (no. 10); p. 1259-1259
Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective. (Gutierrez et al, 2018) Source: Critical Care Medicine; Sep 2018; vol. 46 (no. 9); p. 1402-1410
*Chimeric antigen receptor T-cell therapy (Ogba et al, 2018) Source: JNCCN Journal of the National Comprehensive Cancer Network; Sep 2018; vol. 16 (no. 9); p. 1093-1106
CAR T-cell design: a long road ahead (The Lancet Haematology) Source: The Lancet Haematology; Mar 2018; vol. 5 (no. 3)
*CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies. (Stadtmauer & Mangan, 2017) Source: Journal of the Advanced Practitioner in Oncology; Apr 2017; vol. 8 (no. 3); p. 228-231
Developing infrastructure: Managing patients with cancer undergoing car T-cell therapy (Halton et al, 2017) Source: Clinical Journal of Oncology Nursing; 2017; vol. 21 (no. 2); p. 35-40
Cytokine Release Syndrome: Inpatient care for side effects of CAR T-cell therapy. (Smith & Venella, 2017) Source: Clinical Journal of Oncology Nursing; Apr 2017; vol. 21 ; p. 29-34
* Chimeric antigen receptor T-cell immunotherapy tackles blood cancers. (Brower, 2015) Source: JNCI: Journal of the National Cancer Institute; Apr 2015; vol. 107 (no. 4)
Books in the Christie Library
A Beginner’s Guide to Targeted Cancer Treatments (Vickers, 2018)
We have this book as a hard copy and an ebook
Log in with your OpenAthens password and access the ebook here
Immuno-oncology (Michielin and Coukos, 2015)
See chapter on T-Cell Engineering including therapeutic application
Log in with your OpenAthens password and access the ebook here
CAR-T therapy has been described as a potentially game-changing treatment in the management of cancer patients, and has recently been approved by the NHS for blood cancers.
However, the development of the product and the delivery of CAR-T cell therapy is complex, with the potential for patients to develop specific side effects.
This course outlines the key concepts of CAR-T, and will provide you with the knowledge to recognise and manage the initial toxicity of treatment.